Zepbound vs Wegovy: How They Compare for Weight Loss

Zepbound vs Wegovy is one of the most common questions in weight management today. Both are FDA-approved, once-weekly injectable prescription medications for chronic weight management in eligible adults. The core difference is mechanism: Zepbound (tirzepatide) activates two gut-hormone receptors — GIP and GLP-1 — while Wegovy (semaglutide) activates one. Both are prescribed alongside a reduced-calorie diet and increased physical activity, and neither is appropriate without medical supervision.

What Is Zepbound?

Zepbound is the brand name for tirzepatide, made by Eli Lilly. It is FDA-approved for chronic weight management in adults who have obesity, or who are overweight and have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The same active molecule is sold under the brand name Mounjaro for type 2 diabetes. Same drug, different FDA-approved indication and branding. You can read more about tirzepatide's profile on our tirzepatide reference page.

What Is Wegovy?

Wegovy is the brand name for semaglutide, made by Novo Nordisk. It is FDA-approved for chronic weight management in eligible adults and adolescents. Certain uses also include reducing the risk of major cardiovascular events in adults with established cardiovascular disease who are overweight or have obesity — an indication Zepbound does not share in the same form.

Semaglutide is also marketed as Ozempic for type 2 diabetes and as Rybelsus in oral tablet form. See our Ozempic vs Wegovy comparison for how those two brands differ, or the semaglutide reference page.

Zepbound vs Wegovy: How They Work

This is the heart of the comparison.

Wegovy (semaglutide) is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a hormone your gut releases after eating. That slows stomach emptying, increases satiety, and reduces appetite signaling in the brain.

Zepbound (tirzepatide) is a dual GIP and GLP-1 receptor agonist. It engages the GLP-1 pathway and the glucose-dependent insulinotropic polypeptide (GIP) pathway. Acting on two complementary hormone systems is widely cited as the reason tirzepatide has performed strongly in clinical research. For the underlying pharmacology, see semaglutide vs tirzepatide.

Zepbound vs Wegovy: Key Differences at a Glance

• Active ingredient: Zepbound = tirzepatide; Wegovy = semaglutide.
• Mechanism: Zepbound is a dual GIP/GLP-1 agonist; Wegovy is a single GLP-1 agonist.
• Manufacturer: Eli Lilly (Zepbound); Novo Nordisk (Wegovy).
• Approved use: Both are approved for chronic weight management. Wegovy additionally carries a cardiovascular risk-reduction indication for certain patients.
• Sister brand: Zepbound ↔ Mounjaro; Wegovy ↔ Ozempic and Rybelsus.
• Administration: Both are once-weekly subcutaneous injections via pre-filled pen.

Effectiveness: What the Research Suggests

Head-to-head and comparative clinical research has generally indicated that tirzepatide can produce greater average weight loss than semaglutide for many people. That is the broad direction of the evidence, and it is why Zepbound often draws attention first.

Two important caveats. First, averages are not individuals — response varies substantially from person to person, and plenty of people do very well on semaglutide. Second, "more weight loss" is not the only variable that matters. Tolerability, other health conditions, cardiovascular indications, insurance coverage, and supply can all reasonably tip the decision toward one drug or the other. This is a conversation for your prescriber, not a leaderboard.

Side Effects and Safety

Both medications share a broadly similar side-effect profile, dominated by gastrointestinal effects:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Reduced appetite

Side effects are typically most pronounced when starting treatment or increasing the dose, and often ease over time. This is precisely why clinicians escalate slowly.

Both carry a boxed warning regarding thyroid C-cell tumors observed in rodent studies. Neither is recommended for people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Rarer but serious risks include pancreatitis, gallbladder disease, and kidney problems related to dehydration from GI effects. For a broader framing of peptide-drug risk, see are peptides safe.

How They're Taken

Both Zepbound and Wegovy are once-weekly subcutaneous injections delivered by a pre-filled pen, typically into the abdomen, thigh, or upper arm, on the same day each week. Both begin at a low starting dose and are increased gradually under medical supervision.

Because both are prescription pen products with a prescriber-managed titration schedule, specific dosing is determined by your clinician and is not something to improvise or copy from someone else's experience.

Cost and Insurance Coverage

Both drugs carry high list prices, and what you actually pay varies enormously depending on insurance, employer plan design, and whether weight-management drugs are covered at all — many plans exclude them or require prior authorization and documented BMI criteria.

Both manufacturers have run savings programs for eligible commercially insured patients, and both drugs have experienced supply constraints at various points. Because pricing and coverage shift frequently, verify current specifics with your insurer and pharmacy rather than relying on any figure you read online.

Who Is Typically Eligible?

Broadly, both are indicated for adults with a BMI in the obesity range, or in the overweight range with at least one weight-related comorbidity. Wegovy also has an adolescent indication. Eligibility is a clinical determination that accounts for your full medical history, current medications, and contraindications — including the thyroid and pancreatitis considerations above.

Which Might Be Right for You?

The honest answer is that it depends, and the decision belongs with a licensed clinician. Zepbound's dual mechanism and comparative results make it a common first consideration, but Wegovy's cardiovascular indication, your insurance coverage, your tolerance of GI effects, and drug availability are all legitimate reasons a prescriber may point you one way or the other. Do not start, stop, or switch either medication on your own.

Frequently Asked Questions

Is Zepbound more effective than Wegovy for weight loss?

Comparative clinical research has generally shown greater average weight loss with tirzepatide (Zepbound) than semaglutide (Wegovy). However, individual results vary widely, and the "better" drug depends on your health profile, tolerability, and coverage. Your prescriber can weigh those factors.

Are Zepbound and Wegovy the same as Mounjaro and Ozempic?

They share active ingredients. Zepbound and Mounjaro are both tirzepatide; Wegovy and Ozempic are both semaglutide. The brands differ by FDA-approved indication — weight management versus type 2 diabetes.

Can I take Zepbound or Wegovy without diet and exercise?

Both are approved for use alongside a reduced-calorie diet and increased physical activity. They are not standalone solutions, and outcomes are better when paired with those changes.

Do Zepbound and Wegovy have different side effects?

Their profiles are broadly similar, with gastrointestinal symptoms most common and the same boxed warning regarding thyroid C-cell tumors. Individual tolerance can differ meaningfully between the two.

Can I switch from Wegovy to Zepbound?

Switching is a clinical decision. Prescribers consider your response so far, tolerability, coverage, and supply, and will manage the transition and dose escalation. Never switch on your own.

Where to Go From Here

• Explore the weight-loss peptide hub for the full category.
• Compare the underlying molecules in semaglutide vs tirzepatide.
• Understand the brand overlap in Ozempic vs Wegovy.
• Read the safety pillar: are peptides safe.